Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
09-11 April, 2025
Not Confirmed
Not Confirmed
31 March-01 April, 2025
Plastics Recycling EUPlastics Recycling EU
Not Confirmed
Not Confirmed
01-02 April, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
09-11 April, 2025
Industry Trade Show
Not Confirmed
31 March-01 April, 2025
Plastics Recycling EUPlastics Recycling EU
Industry Trade Show
Not Confirmed
01-02 April, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/our-unmatched-efficiency-and-track-record-of-faster-dmf-filings-give-our-customers-a-critical-competitive-advantage
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/molecular-glue-degraders-lilly-abbvie-sign-billion-dollar-deals-bms-leads-with-three-late-stage-drugs
26 Nov 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/satsuma-pharmaceuticals-and-snbl-receive-fda-acceptance-of-nda-resubmission-of-sts101-for-the-acute-treatment-of-migraine-with-or-without-aura-302316089.html
30 Oct 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/satsuma-pharmaceuticals-and-snbl-resubmits-the-new-drug-application-for-sts101-dihydroergotamine-nasal-powder-for-the-acute-treatment-of-migraine-with-or-without-aura-302292154.html
08 Oct 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/satsuma-pharmaceuticals-and-snbl-announce-publication-of-sts101-dihydroergotamine-nasal-powder-pivotal-phase-3-ascend-study-in-cns-drugs-302270104.html
19 Jan 2024
// PRESS RELEASE
15 Jun 2023
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2023/06/15/2688854/0/en/Satsuma-Pharmaceuticals-and-SNBL-Announce-Three-Abstracts-on-STS101-for-the-Acute-Treatment-of-Migraine-to-be-Presented-at-the-American-Headache-Society-s-65th-Annual-Scientific-Me.html
18 May 2023
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2023/05/18/2672216/0/en/Satsuma-Pharmaceuticals-Announces-FDA-Acceptance-of-505-b-2-NDA-for-STS101-a-Novel-and-Investigational-Dihydroergotamine-DHE-Nasal-Powder-Product-for-the-Acute-Treatment-of-Migrain.html
ABOUT THIS PAGE